Could a diabetes shot heal damaged guts? new trial begins.
NCT ID NCT07297238
First seen Jan 11, 2026 · Last updated May 22, 2026 · Updated 20 times
Summary
This study tests whether a weekly injection of semaglutide (a GLP-1 drug) can improve gut barrier function in adults with short bowel syndrome and intestinal failure. Twenty participants will receive either the drug or a placebo for 28 days, alongside standard care. The goal is to see if the drug helps the gut absorb nutrients better and reduces the need for intravenous nutrition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTESTINAL FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinling Hospital
RECRUITINGNanjing, China, 210002, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jinling Hospital
RECRUITINGNanning, China, 210002, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.